Olga Sorkine-Hornung is a Professor of Computer Science at ETH Zurich and head of the Institute of Visual Computing. She leads the Interactive Geometry Lab, focusing on theoretical and practical advancements in digital content creation, geometry processing, and shape modeling. Current position: ETH Zurich, Department of Computer Science Previous roles: Courant Institute (NYU), Technical University of Berlin Education: BSc and PhD from Tel Aviv University, postdoc at TU Berlin Her research spans shape representation, digital fabrication, computer animation, and fundamental geometry processing. Key contributions include Laplacian surface editing, as-rigid-as-possible deformation, and generalized winding numbers. She works on applications in VR, AR, and autonomous systems. Awards include Test of Time Awards (2024), ACM Fellow (2020), ERC Consolidator Grant (2020), and EUROGRAPHICS Young Researcher Award (2008). She has supervised numerous students and co-developed software libraries like libigl and Instant Meshes . Co-chair roles for SIGGRAPH, Eurographics, and Pacific Graphics Editorial board member for ACM Transactions on Graphics and other journals Keynote speaker at VMV, CVPR, and SIAM conferences Her work bridges mathematical rigor with practical implementation, advancing computer graphics and geometry processing through intuitive algorithms that maintain surface detail while enabling efficient computation.
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.
Rana Hanocka is an Assistant Professor of Computer Science at the University of Chicago, leading the 3DL research group focused on AI-driven 3D geometry processing. She earned her Ph.D. in 2021 from Tel Aviv University under Professors Daniel Cohen-Or and Raja Giryes. Her work explores neural networks for unstructured 3D data, including mesh convolutional networks and self-priors for shape reconstruction. Key research areas include geometric deep learning, human-AI collaboration in 3D modeling, and interpretable neural networks. Notable contributions include MeshCNN (SIGGRAPH 2019) and Point2Mesh (NeurIPS 2020), advancing mesh analysis and point cloud processing. Awards include the 2023 Pazy Research Award and 2020 Rising Star in EECS. Education : Ph.D. Computer Science, Tel Aviv University (2021) Labs/Groups : 3DL Group at UChicago Grants : NSF Grant for AI-driven 3D modeling tools (2023) Research directions emphasize creative human-AI partnerships, unsupervised learning from shape collections, and explainable 3D neural networks. Ongoing projects include style-aware 3D synthesis, interactive segmentation, and multimodal shape interfaces.
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Michael O'Boyle is a Professor at the University of Edinburgh's School of Informatics, where he serves as Director of the ARM Research Centre of Excellence and the EPSRC Centre for Doctoral Training in Pervasive Parallelism. Holding an EPSRC Established Career Research Fellowship, he leads pioneering work in compiler technology for heterogeneous architectures, bridging theoretical advances with practical high-performance computing applications. Professor O'Boyle's research spans multiple cutting-edge areas including heterogeneous code discovery and optimization, neural machine translation for program synthesis, deep neural network system stack optimization, software-defined hardware, and compiler/architecture co-design. His approach integrates constraint analysis, program synthesis, and machine learning to address complex challenges in high-performance computing across diverse hardware platforms. His recent publications reveal a strong trend toward integrating machine learning with traditional compiler techniques, particularly in neural program synthesis, tensor optimization, and architecture-aware compilation. This work represents a paradigm shift in compiler design, moving from rule-based systems to learning-based approaches that can automatically adapt to diverse hardware targets. IEEE/ACM CGO 2025 Distinguished Paper Award for 'Tensorize: Fast Synthesis of Tensor Programs from Legacy Code' IEEE/ACM CGO 2024 Test of Time Award ACM GPCE 2023 Best Paper Award for 'C2TACO: Lifting Tensor Code to TACOM' ACM ASPLOS 2021 Distinguished Paper Award IEEE HPCA 2021 Best Paper Award for 'Prodigy: Improving the Memory Latency of Data-Indirect Irregular Workloads' Professor O'Boyle has successfully mentored numerous PhD students who have secured prominent positions in academia (including at Cambridge, Edinburgh, Leeds, and McGill) and industry (including Meta, NVIDIA, Qualcomm, Huawei, and Microsoft). His research is supported by significant funding from EPSRC, ARM, and European projects including Bonseyes and Transmuter, demonstrating strong international recognition and industry impact. He leads the influential Compiler and Architecture Design (CArD) Group at the University of Edinburgh and is a founder of the HiPEAC Network of Excellence, which has grown into a major European initiative connecting researchers and practitioners in high-performance and embedded computing.
Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.
Michael J. Aziz is the Gene and Tracy Sykes Professor of Materials and Energy Technologies at Harvard University's John A. Paulson School of Engineering and Applied Sciences (SEAS). He serves as Area Chair for Materials Science and Mechanical Engineering and is a Faculty Associate at the Harvard University Center for the Environment. His research focuses on electrochemical engineering for energy and environmental applications, including redox flow batteries, carbon capture, and sustainable energy technologies. Aziz leads the Aziz Group, which develops grid-scale energy storage solutions and innovative methods for CO₂ removal. He holds equity in Quino Energy, a startup commercializing his battery research, and serves as Chief Scientist and Board Member. His work bridges fundamental materials science with practical engineering, emphasizing ClimateTech solutions. Key contributions include aqueous organic redox flow batteries, quinone-based carbon capture systems, and wearable energy storage devices. Education & Affiliations: Affiliated with SEAS since joining Harvard, his academic roles include coordinating the Graduate Consortium for Energy and Environment (2009–2018). His lab (Materials Science Group) is located at McKay 504, with administrative support from Sabrina Azinheira. Research Interests: Aziz's group investigates electrochemical energy storage, CO₂ capture via electrochemical systems, and novel materials for sustainable technologies. They employ advanced techniques like operando electrochemical fluorescence microscopy to study porous electrode dynamics and battery degradation mechanisms. Their work emphasizes scalability and real-world applicability, such as grid-scale battery infrastructure and decarbonization strategies. Recent Trends in Publications: Aziz's recent work emphasizes carbon capture innovations (e.g., acid-base concentration swing methods), hydrogen storage under ambient conditions, and electrochemical synthesis of industrial chemicals like hydrogen peroxide. His group also develops open-source tools like RFBzero for battery modeling and explores bioinspired materials (e.g., self-gelling hydrogel batteries). Awards & Recognition: While no personal awards are explicitly listed in the text, his team members (e.g., Dawei Xi) have received accolades such as the 2025 Carbon Future Young Investigator Award. Aziz's contributions have been recognized through industry partnerships and startup ventures. Advising & Industry Impact: Aziz advises PhD students focusing on electrochemical systems (e.g., Jordan Sosa, Tommy George). His industry engagement includes licensing intellectual property to Quino Energy, which achieved a manufacturing milestone in 2024 for grid-scale battery systems. His research bridges academia and industry, addressing climate challenges through technological innovation. Labs & Teams: The Aziz Group includes interdisciplinary researchers from electrochemistry, chemical engineering, and materials science. Collaborators include institutions like MIT and industry partners. Current projects target next-gen batteries, CO₂ removal systems, and scalable energy storage solutions.
Prof. Dr. Gonzalo Guillén Gosálbez is a Full Professor at the Department of Chemistry and Applied Biosciences , ETH Zürich. He holds a PhD in Process Systems Engineering (UPC, 2005) and has held academic positions at Imperial College London (Reader), University of Manchester (Senior Lecturer), and Universitat Rovira i Virgili (Assistant/Associate Professor). His research focuses on Sustainable Chemical Processes , integrating life cycle assessment, optimization techniques, and planetary boundary analysis to evaluate and design low-carbon technologies. Current position: Full Professor, ETH Zürich (2019–present) Prior roles: Imperial College London (2016–2019), University of Manchester (2014–2016), URV Spain (2008–2014) Education: PhD (UPC, 2005), MEng/BEng (University of Murcia) His research explores CO2 valorization , green methanol synthesis , circular marine fuels , and planetary boundary compliance in energy and chemical systems. Recent work emphasizes machine learning for process modeling, single-atom catalysis , and decentralized ammonia production . Scientific contributions include 15+ peer-reviewed articles (2023–2025) in journals like Nature Chemical Engineering , ACS Sustainable Chemistry & Engineering , and Energy & Environmental Science . Key themes: Optimization of hybrid fossil/renewable carbon systems Environmental impacts of energy transitions Catalyst design for sustainable chemistry Life cycle assessment of emerging technologies Awarded UPC Top Doctoral Student Award and Top National Student Award , he combines process systems engineering with sustainability metrics to address global challenges in chemical and energy systems.
Vikramaditya G. Yadav is an Associate Professor at the University of British Columbia (UBC) in the Department of Chemical and Biological Engineering, Faculty of Applied Science. He directs the Master of Engineering Leadership (MEL) Program in Sustainable Process Engineering and leads the BioFoundry research group. Education: B.A.Sc., University of Waterloo (2007) Ph.D., Massachusetts Institute of Technology (2013) Postdoctoral Associate, Harvard University (2014) His research spans sustainable chemical manufacturing, metabolic engineering, and biotechnology. Key areas include: Designing biosynthetic enzymes for biomass valorization Developing bioremediation strategies for industrial water quality Creating innovative drug delivery systems and tissue engineering solutions Advancing synthetic biology for pharmaceutical and bioenergy applications His recent work focuses on ocular drug delivery, cannabinoid biosynthesis in E. coli, lignin-based nanoparticles for cancer therapy, and computational analysis of plant secondary metabolites. Collaborations with start-ups, industry, and medical labs drive innovation in Canada's bioeconomy. Professional Leadership: Chair, Biotechnology Division of the Chemical Institute of Canada Associate Editor, The Canadian Journal of Chemical Engineering He is affiliated with UBC's BioProducts Institute and contributes to project-based learning pedagogy.
Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Rainer Haag is a Professor at the Department of Chemistry, Freie Universität Berlin, leading the Haag Group in the Institute of Chemistry and Biochemistry. His research focuses on biodegradable and sustainable materials, dynamic hydrogels, and polymeric nanosystems for biomedical applications. Department of Chemistry, Freie Universität Berlin Member of SFB 1449: Dynamic Hydrogels at Biointerfaces Collaborator in the StemGel startup project Co-founder of CSR|Berlin interdisciplinary research institute Research Interests: Development of stimuli-responsive polymers, multivalent virus inhibitors, and functional biointerfaces. Key projects include: Antiviral coatings using heteromultivalent polymers Thermoresponsive hydrogels for stem cell expansion Graphene derivatives for bacterial capture and disinfection Lignin upcycling for sustainable resin materials Supramolecular nanosystems for drug delivery Publication Trends highlight interdisciplinary work in polymer chemistry, nanotechnology, and biomedical applications. Recent articles focus on: 2D polyglycerols for virus interactions Redox-responsive nanogels Mucus-inspired adhesive hydrogels Tumor-targeting micelles Bacterial disinfection using graphene composites Labs & Collaborations include the Polymeric and Supramolecular Nanosystems subgroup, the Dynamic Hydrogels and Biointerfaces team, and partnerships with MIT in developing bioinspired adhesives. His group contributes to DFG-funded SFB 1449 and CSR|Berlin initiatives.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
